🔎 Trials Near Me

Domov › Rak pljuč › North Carolina

Klinične študije za Rak pljuč v North Carolina

50 študij za Rak pljuč išče udeležence na lokacijah v North Carolina.

Mesta v North Carolina

Uradno besedilo študije (angleško)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Cone Health MedCenter Asheboro, Asheboro
  • Cone Health Cancer Center at Alamance Regional, Burlington
  • Wake Forest University at Clemmons, Clemmons
  • in še 7
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04267848

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Duke University, Durham
Vključevanje udeležencevFaza 1/2
Starost 12 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04585750

Distance-Based Exercise to Preserve Function and Prevent Disability

  • Novant Health Cancer Institute - Kernersville, Kernersville
  • Novant Health Cancer Institute - Mount Airy, Mount Airy
  • Novant Health Forsyth Medical Center, Winston-Salem
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07059884

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • AdventHealth Infusion Center Asheville, Asheville
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • AdventHealth Infusion Center Haywood, Clyde
  • in še 6
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

  • Southeastern Medical Oncology Center-Clinton, Clinton
  • Southeastern Medical Oncology Center-Goldsboro, Goldsboro
  • Southeastern Medical Oncology Center-Jacksonville, Jacksonville
Vključevanje udeležencevFaza 3
Starost 70 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06096844

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  • Novant Health Presbyterian Medical Center, Charlotte
  • Southeastern Medical Oncology Center-Clinton, Clinton
  • Southeastern Medical Oncology Center-Goldsboro, Goldsboro
  • in še 7
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT04181060

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • Duke Cancer Center Cary, Cary
  • Durham VA Medical Center, Durham
  • Duke University Medical Center, Durham
  • in še 2
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06498635

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  • Carolinas Medical Center, Charlotte
  • Duke Cancer Center, Durham
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06765109

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06881784

A Study of PHN-012 in Patients With Advanced Solid Tumors

  • PHN-012-001 Site, Durham
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07127874

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  • GSK Investigational Site, Wilson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT07099898

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • FirstHealth Cancer Center, Pinehurst
  • FirstHealth Moore Regional Hospital, Pinehurst
  • Carolina Cancer Research Center, Wilson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07222566

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  • Messino Cancer Centers Asheville, Asheville
  • Duke University Medical Center, Durham
  • FirstHealth Cancer Center, Pinehurst
Vključevanje udeležencevFaza 3
Starost 18–100 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05920356

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Brody School of Medicine at East Carolina University, Greenville
  • ECU Health Medical Center, Greenville
  • Carolina Cancer Research Center, Wilson
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06758401

A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)

  • GSK Investigational Site, Wilson
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07602855

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Fletcher Hospital, Inc. dba AdventHealth Hendersonville, Hendersonville
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06712316

Study of Trilaciclib and Lurbinectidin

  • Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT05578326

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

  • Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07685938

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Atrium Health Cabarrus/LCI-Concord, Concord
  • Wake Forest University Health Sciences, Winston-Salem
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06287775

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Duke University School of Medicine, Durham
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT05786924

Effects of Infusion Timing on Treatment Response in Solid Tumors

  • University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT07630168

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • University of North Carolina Medical Center, Chapel Hill
  • Duke Cancer Institute, Durham
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 8. sep. 2026 · NCT06119581

The Vanguard Study: Testing a New Way to Screen for Cancer

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • Durham VA Medical Center, Durham
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 45–75 · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT06995898

Health Education Approach to Lung Screening

  • University of North Carolina-Chapel Hill, Carrboro
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 50–80 · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT06070870

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

  • Atrium Health Stanly/LCI-Albemarle, Albemarle
  • Duke Cancer Center Cary, Cary
  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill
  • in še 35
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT05624996

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Charlotte
  • Xencor Investigative Site, Durham
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT05433142

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Duke University Medical Center, Durham
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 15. jul. 2026 · NCT05652686

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

  • Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 14. jul. 2026 · NCT06896162

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

  • Levine Cancer Institute, Charlotte
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 40–54 · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT04577599

Integrated Cancer Repository for Cancer Research

  • Cape Fear Valley Health System, Fayetteville
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 19–110 · Vsi spoli · Posodobljeno 29. jun. 2026 · NCT02012699

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

  • University of North Carolina, Chapel Hill
Vključevanje udeležencevFaza 2
Starost 18–70 · Vsi spoli · Posodobljeno 26. jun. 2026 · NCT04614103

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

  • Research Site, Durham
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 10. jun. 2026 · NCT06835569

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Durham VA Medical Center, Durham
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 3. jun. 2026 · NCT05642572

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

  • Duke Cancer Center, Durham
  • Carolina BioOncology Institute, Huntersville
Vključevanje udeležencevFaza 1
Starost 18 in več · Vsi spoli · Posodobljeno 3. jun. 2026 · NCT06040541

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

  • University of North Carolina at Chapel Hill, Chapel Hill
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 14. maj 2026 · NCT06922591

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
Vključevanje udeležencevFaza 2
18 Minutes · Vsi spoli · Posodobljeno 5. maj 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

  • Durham VA Medical Center, Durham
  • FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 5. maj 2026 · NCT06616584

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • FirstHealth Cancer Center, Pinehurst
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 28. apr. 2026 · NCT05168566

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.